MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.
Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets. 2014 Jan; 15(1):114-23.